Study populations in conventional clinical trials for anti-tumor necrosis factor (TNF) agents in rheumatoid arthritis (RA) have comprised a largely homogeneous patient group with high disease activity and no prior anti-TNF experience, reflecting a small proportion of patients in routine clinical care [1–5]. The gene discussed is TNF; the disease is rheumatoid arthritis.